[Multiple system atrophy]

Nathalie Damon-Perrière1, François Tison, Wassilios G Meissner

  • 1Service de neurologie, Centre de référence national maladie rare atrophie multisystématisée, CHU de Bordeaux, Hôpital du Haut-Lévêque, Pessac.

Insights

Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative disease. Diagnosis relies on clinical symptoms and imaging, with supportive care improving quality of life.

Area of Science:

  • Neuroscience
  • Neurology
  • Pathology

Context:

  • Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder with unknown etiology.
  • It is the most frequent disorder among atypical parkinsonism, affecting 2-5 per 100,000 inhabitants.
  • Characterized by rapidly progressing clinical symptoms and a mean survival of 6-9 years.

Purpose:

  • To outline the diagnostic criteria for Multiple System Atrophy (MSA).
  • To describe the clinical presentation, diagnostic features, and management strategies for MSA.
  • To highlight the importance of supportive care in improving the quality of life for MSA patients.

Summary:

  • Diagnosis of MSA is based on revised 2008 consensus criteria, categorizing cases as "possible", "probable", or "definite".
  • Definite MSA requires post-mortem confirmation of specific neuropathological findings.
  • "Possible" and "probable" diagnoses rely on the presence and severity of parkinsonism, cerebellar dysfunction, autonomic failure, and pyramidal signs.
  • Brain MRI findings like putaminal atrophy, "hot cross bun sign", and MCP hyperintensities aid diagnosis.
  • Autonomic function testing (cardiovascular, urodynamic, anal sphincter EMG) is crucial for diagnosing autonomic failure.
  • While levodopa may offer limited benefit, specific therapies exist for autonomic dysfunction, and physical, speech, and occupational therapies are vital for symptom management and quality of life.

Impact:

  • Improved diagnostic accuracy for Multiple System Atrophy (MSA).
  • Enhanced understanding of MSA's clinical spectrum and progression.
  • Provides a framework for multidisciplinary management and supportive care strategies to improve patient outcomes and quality of life.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...